Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
1 "Jiaohui Pang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Gynecologic cancer
Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation
Yuchun Wei, Chuqing Wei, Liang Chen, Ning Liu, Qiuxiang Ou, Jiani C. Yin, Jiaohui Pang, Zhenhao Fang, Xue Wu, Xiaonan Wang, Dianbin Mu, Yang Shao, Jinming Yu, Shuanghu Yuan
Cancer Res Treat. 2022;54(4):1209-1218.   Published online January 17, 2022
DOI: https://doi.org/10.4143/crt.2021.963
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Neoadjuvant therapy modality can increase the operability rate and mitigate pathological risks in locally advanced cervical cancer, but treatment response varies widely. It remains unclear whether genetic alterations correlate with the response to neoadjuvant therapy and disease-free survival (DFS) in locally advanced cervical cancer.
Materials and Methods
A total of 62 locally advanced cervical cancer (stage IB-IIA) patients who received neoadjuvant chemoradiation plus radical hysterectomy were retrospectively analyzed. Patients’ tumor biopsy samples were comprehensively profiled using targeted next generation sequencing. Pathologic response to neoadjuvant treatment and DFS were evaluated against the association with genomic traits.
Results
Genetic alterations of PIK3CA were most frequent (37%), comparable to that of Caucasian populations from The Cancer Genome Atlas. The mutation frequency of genes including TERT, POLD1, NOS2, and FGFR3 was significantly higher in Chinese patients whereas RPTOR, EGFR, and TP53 were underrepresented in comparison to Caucasians. Germline mutations were identified in 21% (13/62) of the cohort and more than half (57%) had mutations in DNA damage repair genes, including BRCA1/2, TP53 and PALB2. Importantly, high tumor mutation burden, TP53 polymorphism (rs1042522), and KEAP1 mutations were found to be associated with poor pathologic response to neoadjuvant chemoradiation treatment. KEAP1 mutations, PIK3CA-SOX2 co-amplification, TERC copy number gain, and TYMS polymorphism correlated with an increased risk of disease relapse.
Conclusion
We report the genomic profile of locally advanced cervical cancer patients and the distinction between Asian and Caucasian cohorts. Our findings highlight genomic traits associated with unfavorable neoadjuvant chemoradiation response and a higher risk of early disease recurrence.

Citations

Citations to this article as recorded by  
  • Cytokine Gene Variants as Risk Predictors and Prognostic Biomarkers for Cervix Cancer: A Revisit
    Atar Singh Kushwah, Maneesh Kumar Gupta, Kirti Srivastava, Monisha Banerjee
    Current Cancer Therapy Reviews.2026; 22(3): 234.     CrossRef
  • Distinct Molecular and Prognostic Profiles of Left‐ and Right‐Sided Colorectal Cancer Revealed by NGS Analysis: The Role of SMAD4 and SETD2 Mutations
    Wenlei Zhao, Yuxuan Qiu, Na Bai, Chunhong He, Jiani C. Yin, Qianru Xu, Kaiyu Jian, Baolei Jia, Lin Jiang, Feng Liang
    Cancer Medicine.2026;[Epub]     CrossRef
  • Enriched NKX2-1 Mutations in Bronchiolar Adenoma Variants: Evidence for Malignant Transformation or an Indolent Entity
    Lu-yao Li, Gong-ming Dong, Yi-xin Ma, Jie Liu, Yan Shi, Fu-quan Jia, Guan-jun Zhang
    Current Medical Science.2026; 46(1): 116.     CrossRef
  • PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability
    Alessandro Ottaiano, Carmine Picone, Mariachiara Santorsola, Massimiliano Berretta, Carmen Cutolo, Andrea Belli, Francesco Izzo, Nadia Di Carluccio, Aniello Acampora, Luca Tarotto, Salvatore Stilo, Marco Correra, Maurizio Capuozzo, Anna Chiara Carratù, Mi
    Cancers.2026; 18(17): 2798.     CrossRef
  • BRCA1 Mutations and Their Consequences in Multiple Cancers: Molecular Insights and Emerging Therapeutic Strategies
    Swaroop Kumar Pandey, Swarnima Paliwal, Braj Bhushan Mall
    Current Cancer Therapy Reviews.2026; 22(5): 521.     CrossRef
  • Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancer
    Chenjing Zhu, Zhen Gong, Ping Yin, Jian Huang, Dan He, Biqing Zhu, Yaqin Wu, Hairong Wang, Yaru Zhang, Qifan Jing, Jiani C Yin, Yue Li, Jianyao Liu, Huanhuan Hu, Shuyue Xiao, Zhihua Sun, Hanzi Xu
    The Oncologist.2025;[Epub]     CrossRef
  • A Comparative Analysis of Usual- and Gastric-Type Cervical Adenocarcinoma in a Japanese Population Reveals Distinct Clinicopathological and Molecular Features with Prognostic and Therapeutic Insights
    Umme Farzana Zahan, Hasibul Islam Sohel, Kentaro Nakayama, Masako Ishikawa, Mamiko Nagase, Sultana Razia, Kosuke Kanno, Hitomi Yamashita, Shahataj Begum Sonia, Satoru Kyo
    International Journal of Molecular Sciences.2025; 26(15): 7469.     CrossRef
  • Comprehensive characterization of PKHD1 mutation in human colon cancer
    Lu Han, Fangming Gong, Xuxiaochen Wu, Wanxiangfu Tang, Hua Bao, Yue Wang, Daizhenru Wang, Yulan Sun, Peng Li
    Cancer Medicine.2024;[Epub]     CrossRef
  • PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer
    Wenhan Li, Yuhui Huang, Man Xiao, Jing Zhao, Shi Du, Zehua Wang, Sha Hu, Lu Yang, Jing Cai
    iScience.2024; 27(3): 109160.     CrossRef
  • Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real‐world cohort analysis
    Yi Sun, Shilei Qin, Song Wang, Jiaohui Pang, Qiuxiang Ou, Weiquan Liang, Hai Zhong
    The Journal of Pathology: Clinical Research.2024;[Epub]     CrossRef
  • PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer
    Cong Wang, Lijun Liu, Xia Li, Jia Lei, Yiqian Li, Zhibo Shen, Huirong Shi, Yan Cheng
    Future Oncology.2024; 20(20): 1415.     CrossRef
  • A biomarker exploration in small-cell lung cancer for brain metastases risk and prophylactic cranial irradiation therapy efficacy
    Li Li, Ning Liu, Tao Zhou, Xueting Qin, Xiaoyu Song, Song Wang, Jiaohui Pang, Qiuxiang Ou, Yong Wang, Dexian Zhang, Jiaran Li, Fuhao Xu, Shuming Shi, Jinming Yu, Shuanghu Yuan
    Lung Cancer.2024; 196: 107959.     CrossRef
  • Prospects of POLD1 in Human Cancers: A Review
    Michał Gola, Przemysław Stefaniak, Janusz Godlewski, Barbara Jereczek-Fossa, Anna Starzyńska
    Cancers.2023; 15(6): 1905.     CrossRef
  • Copy-number-gain of telomerase reverse transcriptase (hTERT) is associated with an unfavorable prognosis in esophageal adenocarcinoma
    Su Ir Lyu, Felix C. Popp, Adrian Georg Simon, Anne Maria Schultheis, Thomas Zander, Caroline Fretter, Wolfgang Schröder, Christiane J. Bruns, Thomas Schmidt, Alexander Quaas, Karl Knipper
    Scientific Reports.2023;[Epub]     CrossRef
  • 12,526 View
  • 186 Download
  • 14 Web of Science
  • 14 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP